Barclays’s CinCor Pharma, Inc. Common Stock CINC Stock Holding History

Barclays’s Portfolio CINC Stock Details CINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6,671	Closed	-$82K	–	5527
2022 Q4	$82K	Buy	6,671 +3,963	+146%	+$94.4K	﹤0.01%	4342
2022 Q3	$89K	Buy	2,708 +2,036	+303%	+$57.5K	﹤0.01%	3580
2022 Q2	$13K	Sell	672 -1,212	-64%	-$23.2K	﹤0.01%	4555
2022 Q1	$34K	Buy	+1,884	New	+$38.7K	﹤0.01%	4268

Barclays's CINC Position: Q1 2023 in Review

Barclays sold out of CinCor Pharma, Inc. Common Stock (CINC) in Q1 2023, closing a stake of 6,671 shares — an estimated $82K sold.

Barclays first reported a position in CINC in Q1 2022 and held it in 4 quarters. The position peaked at $89K in Q3 2022. 0 funds tracked by Wall St. Rank hold CINC as of Q1 2023.

Barclays reported no remaining CinCor Pharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Barclays sold 6,671 CinCor Pharma, Inc. Common Stock shares in Q1 2023, an estimated $82K.
Barclays first reported a position in CinCor Pharma, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
Barclays's CinCor Pharma, Inc. Common Stock position peaked at $89K in Q3 2022.
0 funds tracked by Wall St. Rank held CinCor Pharma, Inc. Common Stock as of Q1 2023.

Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.